NDA 050718 · Baxter Hlthcare Corp
Doxil (Liposomal)
Doxorubicin Hydrochloride · Injection
Accelerated approvalOrphanLast checked: Nov 19, 2026Latest source record: Mar 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Nov 17, 1995
Approved uses
7
Original approval plus efficacy supplements
Registered trials
2,822
757 Phase 3, 308 recruiting
FAERS reports
32,988
30,133 serious, 5,456 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS • DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m 2 to 550 mg/m 2 . Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion and during and after treatment [see Warnings and Precautions (5.1) ] . • Serious, life-threatening, and fatal infusion-related reactions can occur with DOXIL liposomal infusion Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions [see Warnings and Precautions (5.2) ] . WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS...
What it is approved for
From the label in effect Mar 10, 2026.
DOXIL liposomal infusion is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) • Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer DOXIL liposomal infusion is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi’s Sarcoma DOXIL liposomal infusion is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma DOXIL liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.
Mechanism: The active ingredient of DOXIL liposomal infusion is doxorubicin hydrochloride. The mechanism of action of doxorubicin hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 2015 Supplement 48 · Efficacy LetterLabel
- Jun 10, 2008 Supplement 33 · Efficacy LabelSummary ReviewLetter
- May 17, 2007 Supplement 29 · Efficacy · priority review LabelLetter
- Jan 28, 2005 Supplement 20 · Efficacy LabelLetter
- Oct 27, 2004 Supplement 19 · Efficacy ReviewLabelLetter
- Jun 28, 1999 Supplement 6 · Efficacy · priority review LabelReviewLetter
- Nov 17, 1995 Original approval · Type 3 - New Dosage Form
2 products under this application
- DOXIL (LIPOSOMAL) · DOXORUBICIN HYDROCHLORIDE 20MG/10ML (2MG/ML) · INJECTABLE, LIPOSOMAL, INJECTION · Prescription · TE AB
- DOXIL (LIPOSOMAL) · DOXORUBICIN HYDROCHLORIDE 50MG/25ML (2MG/ML) · INJECTABLE, LIPOSOMAL, INJECTION · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxorubicin" as an intervention, any sponsor and status, largest first.
- Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell LineStatus unknown
Cairo UniversityAcademic, hospital or other
NCT05456022 · 1,000,000 participants (planned) · Start Jul 2022 · Primary completion Dec 2023
Drug: Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT) and 1 more · For: Oral Cancer
Sites: Cairo, Egypt
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use3,874
- febrile neutropenia3,562
- neutropenia2,221
- pyrexia1,828
- disease progression1,808
- product use in unapproved indication1,758
- nausea1,651
- anaemia1,539
- alopecia1,533
- vomiting1,328
- thrombocytopenia1,270
- diarrhoea1,156
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 365 |
| 2005 | 434 |
| 2006 | 431 |
| 2007 | 531 |
| 2008 | 576 |
| 2009 | 364 |
| 2010 | 392 |
| 2011 | 590 |
| 2012 | 769 |
| 2013 | 589 |
| 2014 | 466 |
| 2015 | 1,241 |
| 2016 | 1,079 |
| 2017 | 1,587 |
| 2018 | 1,975 |
| 2019 | 2,308 |
| 2020 | 3,545 |
| 2021 | 2,306 |
| 2022 | 3,066 |
| 2023 | 3,284 |
| 2024 | 2,933 |
| 2025 | 2,386 |
| 2026 | 1,771 |
Recalls
1 FDA enforcement reports for this application.
Aug 24, 2023 · Class II · Terminated
CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Multicenter Study
- Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity.
Ozcan M, Guo Z, Valenzuela Ripoll C, et al. · Cell Metab 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
Pervaiz N, Colterjohn N, Farrokhyar F, et al. · Cancer 2008 · Meta-Analysis, Systematic Review
- Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways.
Hiensch AE, Bolam KA, Mijwel S, et al. · Acta Physiol (Oxf) 2020 · Meta-Analysis, Systematic Review
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.